PuSH - Publication Server of Helmholtz Zentrum München

60 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Hess, J. et al.: A five-microRNA signature predicts survival and disease control of patients with head and neck cancer negative for HPV-infection. Clin. Cancer Res. 25, 1505-1516 (2019)
2.
Hess, J. et al.: A five-microRNA-signature predicts recurrence and survival in HPV-negative HNSCC. Strahlenther. Onkol. 195, S25-S25 (2019)
3.
Klymenko, O. et al.: Patient-derived HNSCC cell lines and subclones reflect inter- and intra-tumoral heterogeneity regarding genomic copy number alterations and radiation response. Strahlenther. Onkol. 195, S75-S76 (2019)
4.
Osterode, E.* et al.: Evaluation of CD44v6 targeting strategies in HNSCC. Strahlenther. Onkol. 195, S176-S176 (2019)
5.
Piehlmaier, D. et al.: In-vitro and in-vivo characterization of a glioblastoma cell line panel. Strahlenther. Onkol. 195, S63-S64 (2019)
6.
Schötz, U. et al.: Inherent resistance of head and neck tumors: Cellular senescence and associated cyokine production as key mechanisms in vitro and in vivo. Strahlenther. Onkol. 195, S76-S76 (2019)
7.
Unger, K. et al.: Validation of a 4-miRNA prognosticator allowing for improved risk stratification of glioblastoma patients in combination with MGMT promoter methylation status. Strahlenther. Onkol. 195, S63-S63 (2019)
8.
Weber, J.* et al.: PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice. Nat. Commun. 10:1415 (2019)
9.
Wintergerst, L. et al.: A 16q24.3 4-gene mRNA signature predicts outcome in radio(chemo)therapy-treated head and neck squamous cell carcinoma. Strahlenther. Onkol. 195, S24-S25 (2019)
10.
Baumeister, P. et al.: High expression of EpCAM and Sox2 is a positive prognosticator of clinical outcome for head and neck carcinoma. Sci. Rep. 8:14582 (2018)
11.
Klymenko, O. et al.: HNSCC derived cell lines and subclones differ in genomic copy number changes and radiation response. Radiother. Oncol. 127, S1266-S1267 (2018)
12.
Maihoefer, C. et al.: Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". Radiat. Oncol. 13:123 (2018)
13.
Mueller, S.* et al.: Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 554, 62-68 (2018)
14.
Mueller, S.* et al.: Evolutionary trajectories and KRAS gene dosage define pancreatic cancer phenotypes. Cancer Res. 78 (2018)
15.
Pan, M.* et al.: EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers. PLoS Biol. 16:e2006624 (2018)
16.
Schoetz, U.* et al.: Prognostic biomarkers and targets for personalization of radiotherapy of HNSCC: CD44v6. Radiother. Oncol. 127, S251-S251 (2018)
17.
Wilke, C. et al.: Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer. Int. J. Cancer 142, 573-583 (2018)
18.
Wilke, C. et al.: A genomic copy number signature predicts radiation exposure in post-Chernobyl breast cancer. Int. J. Cancer 143, 1505-1515 (2018)
19.
Wintergerst, L. et al.: A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC). Mol. Oncol., accepted (2018)
20.
Hall, J.* et al.: Ionizing radiation biomarkers in epidemiological studies – An update. Mutat. Res.- Rev. Mutat. Res. 771, 59-84 (2017)